Food and Drugs Act (R.S.C., 1985, c. F-27)

Act current to 2017-11-06 and last amended on 2017-06-22. Previous Versions

Devices

Marginal note:Prohibited sales of devices

 No person shall sell any device that, when used according to directions or under such conditions as are customary or usual, may cause injury to the health of the purchaser or user thereof.

  • R.S., c. F-27, s. 19.
Marginal note:Deception, etc., regarding devices
  •  (1) No person shall label, package, treat, process, sell or advertise any device in a manner that is false, misleading or deceptive or is likely to create an erroneous impression regarding its design, construction, performance, intended use, quantity, character, value, composition, merit or safety.

  • Marginal note:Devices labelled or packaged in contravention of regulations

    (2) A device that is not labelled or packaged as required by, or is labelled or packaged contrary to, the regulations shall be deemed to be labelled or packaged contrary to subsection (1).

  • R.S., c. F-27, s. 20;
  • 1976-77, c. 28, s. 16.
Marginal note:Where standard prescribed for device

 Where a standard has been prescribed for a device, no person shall label, package, sell or advertise any article in such a manner that it is likely to be mistaken for that device, unless the article complies with the prescribed standard.

  • R.S., c. F-27, s. 21.

Therapeutic Products

Marginal note:Power to require information — serious risk
  •  (1) If the Minister believes that a therapeutic product may present a serious risk of injury to human health, the Minister may order a person to provide the Minister with information that is in the person’s control and that the Minister believes is necessary to determine whether the product presents such a risk.

  • Marginal note:Disclosure —  serious risk

    (2) The Minister may disclose confidential business information about a therapeutic prod­uct without notifying the person to whose business or affairs the information relates or obtaining their consent, if the Minister believes that the product may present a serious risk of injury to human health.

  • Marginal note:Disclosure —  health or safety

    (3) The Minister may disclose confidential business information about a therapeutic prod­uct without notifying the person to whose business or affairs the information relates or obtaining their consent, if the purpose of the disclosure is related to the protection or promotion of human health or the safety of the public and the disclosure is to

    • (a) a government;

    • (b) a person from whom the Minister seeks advice; or

    • (c) a person who carries out functions relating to the protection or promotion of human health or the safety of the public.

  • Definition of government

    (4) In this section, government means any of the following or their institutions:

    • (a) the federal government;

    • (b) a corporation named in Schedule III to the Financial Administration Act;

    • (c) a provincial government or a public body established under an Act of the legislature of a province;

    • (d) an aboriginal government as defined in subsection 13(3) of the Access to Information Act;

    • (e) a government of a foreign state or of a subdivision of a foreign state; or

    • (f) an international organization of states.

  • 2014, c. 24, s. 3.
Marginal note:Modification or replacement — labelling or packaging

 The Minister may, if he or she believes that doing so is necessary to prevent injury to health, order the holder of a therapeutic product authorization that authorizes the import or sale of a therapeutic product to modify the product’s label or to modify or replace its package.

  • 2014, c. 24, s. 3.
Marginal note:Minister’s powers — risk of injury to health
  •  (1) If the Minister believes that a therapeutic product presents a serious or imminent risk of injury to health, he or she may order a person who sells the product to

    • (a) recall the product; or

    • (b) send the product, or cause it to be sent, to a place specified in the order.

  • Marginal note:Recall order — corrective action

    (2) For greater certainty, if the Minister makes an order under paragraph (1)(a) and believes that corrective action is an effective means of dealing with the risk, the order may require the person who sells the product to, instead of requesting the product’s return, request the product’s owner or user to allow corrective action to be taken in respect of the product and then take that corrective action, or cause it to be taken, if the request is accepted.

  • Marginal note:Prohibition — selling

    (3) Subject to subsection (5), no person shall sell a therapeutic product that the Minister orders them, or another person, to recall.

  • Marginal note:Power to authorize sale

    (4) The Minister may authorize a person to sell a therapeutic product, with or without conditions, even if the Minister has ordered them, or another person, to recall it.

  • Marginal note:Exception

    (5) A person does not contravene subsection (3) if they sell a therapeutic product that they have been authorized under subsection (4) to sell, provided that they sell it in accordance with any conditions that the Minister establishes.

  • Marginal note:Contravention of unpublished order

    (6) No person shall be convicted of an offence for the contravention of subsection (3) unless it is proved that, at the time of the alleged contravention, the person had been notified of the recall order or reasonable steps had been taken to bring the purport of the recall order to the notice of those persons likely to be affected by it.

  • 2014, c. 24, s. 3.
Marginal note:Statutory Instruments Act
  •  (1) For greater certainty, orders made under any of sections 21.1 to 21.3 are not statutory instruments within the meaning of the Statutory Instruments Act.

  • Marginal note:Availability of orders

    (2) The Minister shall ensure that any order made under any of sections 21.1 to 21.3 is publicly available.

  • 2014, c. 24, s. 3.
Marginal note:Injunction
  •  (1) If, on the application of the Minister, it appears to a court of competent jurisdiction that a person has done, is about to do or is likely to do anything that constitutes or is directed toward the commission of an offence under this Act in respect of a therapeutic product, the court may issue an injunction ordering the person, who is to be named in the application, to

    • (a) refrain from doing anything that it appears to the court may constitute or be directed toward the commission of the offence; or

    • (b) do anything that it appears to the court may prevent the commission of the offence.

  • Marginal note:Notice

    (2) No injunction is to be issued under subsection (1) unless 48 hours’ notice is served on the party or parties who are named in the application or unless the urgency of the situation is such that service of notice would not be in the public interest.

  • 2014, c. 24, s. 3.
Marginal note:False or misleading information — therapeutic products

 No person shall knowingly make a false or misleading statement to the Minister  —  or knowingly provide him or her with false or misleading information  —  in connection with any matter under this Act concerning a therapeutic product.

  • 2014, c. 24, s. 3.
Marginal note:Terms and conditions of authorizations

 The holder of a therapeutic product authorization shall comply with the terms and conditions of the authorization that are imposed under regulations made under paragraph 30(1.2)(b).

  • 2014, c. 24, s. 3.
Marginal note:Clinical trials and investigational tests

 The holder of a therapeutic product authorization referred to in paragraph 30(1.2)(c) shall ensure that prescribed information concerning the clinical trial or investigational test is made public within the prescribed time and in the prescribed manner.

  • 2014, c. 24, s. 3.
Marginal note:Health care institutions to provide information

 A prescribed health care institution shall provide the Minister, within the prescribed time and in the prescribed manner, with prescribed information that is in its control about a serious adverse drug reaction that involves a therapeutic product or a medical device incident that involves a therapeutic product.

  • 2014, c. 24, s. 5.
 
Date modified: